Farde L
Department of Psychiatry and Psychology, Karolinska Institute, Stockholm, Sweden.
Psychopharmacology (Berl). 1992;107(1):23-9. doi: 10.1007/BF02244961.
Pharmacological effects were recorded and time course for receptor binding in brain was followed by positron emission tomography after IV injection of the selective D1-dopamine receptor antagonist SCH 23390 in four healthy subjects in doses of 310-810 micrograms. Akathisia, the syndrome of motor restlessness, appeared after the three highest doses. The akathisia was transient and occurred only when [11C]SCH 23390 binding in the basal ganglia was at a high level with a central D1-dopamine receptor occupancy of 45-59%. The D2-dopamine receptor antagonist [11C]raclopride was injected IV into 20 healthy subjects and 13 schizophrenic patients. Akathisia appeared in 14 healthy subjects and 7 patients and coincided with maximal [11C]raclopride binding in the basal ganglia. The findings for [11C]raclopride and [11C]SCH 23390 are the first demonstration of a relationship between time courses for radioligand binding in the human brain and simultaneously induced pharmacological effects.
在4名健康受试者中静脉注射剂量为310 - 810微克的选择性D1 - 多巴胺受体拮抗剂SCH 23390后,记录其药理作用,并通过正电子发射断层扫描跟踪脑中受体结合的时间进程。静坐不能,即运动不安综合征,在三个最高剂量后出现。静坐不能是短暂的,仅在基底神经节中[11C]SCH 23390结合处于高水平且中枢D1 - 多巴胺受体占有率为45 - 59%时发生。将D2 - 多巴胺受体拮抗剂[11C]雷氯必利静脉注射到20名健康受试者和13名精神分裂症患者体内。14名健康受试者和7名患者出现了静坐不能,且与基底神经节中[11C]雷氯必利的最大结合同时发生。[11C]雷氯必利和[11C]SCH 23390的研究结果首次证明了人脑放射性配体结合的时间进程与同时诱导的药理作用之间的关系。